Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,542 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypercarbia
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Completed Phase 1Phase 2 Interventional Results available

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis

NCT01434121
Conditions
Sepsis, Septic Shock, Hypotension, Acute Lung Injury
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Vutrisiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
La Mesa, California • Los Angeles, California • Stanford, California + 13 more
Conditions
Traumatic Brain Injury, Posttraumatic Epilepsy
Interventions
Allopregnanolone injection, Placebo injection
Drug
Lead sponsor
Michael A. Rogawski, MD, PhD
Other
Eligibility
16 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Leprosy Skin Test Antigens Trial

NCT00128193
Conditions
Leprosy
Interventions
Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Fort Collins, Colorado
Terminated Phase 4 Interventional Results available

Fremanezumab, Migraine and Sleep

NCT04693533
Conditions
Migraine Disorders, Sleep Disorder
Interventions
Fremanezumab Prefilled Syringe [Ajovy]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Asthma
Interventions
Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Riverside, California + 18 more
Conditions
Abortion, Dilation and Evacuation, Hemorrhage, Blood Loss
Interventions
intravenous oxytocin, Intravenous Fluids and Electrolytes
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Honolulu, Hawaii • Seattle, Washington
Conditions
Major Depressive Disorder (MDD)
Interventions
Adalimumab Biosimilars Injection, Placebo
Drug · Other
Lead sponsor
Daniel Moriarity
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Prevention of Chikungunya Virus Infection
Interventions
mRNA-1944, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Conditions
Elective Orthopedic Surgery
Interventions
Midazolam, Propofol, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cognitive Impairments, Schizotypal Personality Disorder
Interventions
DAR-0100A, Placebo
Drug
Lead sponsor
Larry J. Siever
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005
Conditions
Major Depressive Disorder
Interventions
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - fMRI

NCT02566356
Conditions
Schizophrenia, Oxytocin, Social Cognition, Functional Magnetic Resonance Imaging (fMRI)
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
San Francisco, California
Completed No phase listed Observational

Long Term Follow Up KET-PD

NCT06164756
Conditions
Parkinson's Disease, Depression
Interventions
Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145
Conditions
Japanese Encephalitis
Interventions
ChimeriVax™-JE, JE-VAX®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Conditions
Variola Major (Smallpox)
Interventions
Placebo, MVA-BN
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
50
States / cities
Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more